search for


Original Article
Delta Neutrophil Index as an Early Marker for Distinguishing Myeloid from Childhood Acute Leukemia
Clin Pediatr Hematol Oncol 2018;25:128-35.
Published online October 31, 2018
© 2018 Korean Society of Pediatric Hematology-Oncology and Korean Society for Pediatric Neuro-Oncology

Joon Pyo Hong, M.D.1, Sohyun Kim, M.D.1, Byuh Ree Kim, M.D.1, Seo Hee Yoon, M.D.2, Seung Min Hahn, M.D.3 and Moon Kyu Kim, M.D.2

1Department of Pediatrics, Yonsei University College of Medicine, Divisions of 2Pediatric Emergency Medicine and
3Pediatric Hematology and Oncology, Yonsei University College of Medicine, Yonsei University Health System, Seoul, Korea
Correspondence to: Moon Kyu Kim
Division of Pediatric Emergency Medicine, Department of Pediatrics, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Tel: +82-2-2228-2067
Fax: +82-2-393-9118
Received September 18, 2018; Revised September 28, 2018; Accepted October 6, 2018.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background: The accurate and early diagnosis of acute myeloid leukemia (AML) is important to choose proper treatment option depending on the risk stratification. The delta neutrophil index (DNI) is a relatively new blood marker that indicates the proportion of immature granulocytes in peripheral blood circulation. This study aimed to evaluate the diagnostic value of the DNI for detecting AML in the early phase of acute leukemia.
Methods: We retrospectively analyzed laboratory tests and bone marrow study results of 163 pediatric patients with acute leukemia admitted to the emergency department, who were diagnosed with acute leukemia. An automatic analyzer (ADVIA 2120 Hematology System; Siemens Healthcare Diagnostics, Forchheim, Germany) was used to measure the DNI in the peripheral blood of each patient.
Results: The mean DNI was significantly different between the AML (N=39) and non-AML (N=124) groups (P<0.05), and the DNI was the only significant marker for predicting AML in patients with acute leukemia (odds ratio, 1.328; P<0.05). The DNI more than 4.4% has the highest predictability for distinguishing the patients with AML from the patients with acute leukemia. The mean DNI of the acute promyelocytic leukemia (APL, N=8) group was statistically higher than that of the non-APL group (N=31, P=0.019), but the DNI was not significant in the univariate logistic regression analysis.
Conclusion: The DNI might be a promising peripheral blood marker for predicting AML in the early work-up of patients with acute leukemia.
Keywords: Leukemia, Child, Acute myeloid leukemia
  1. Linabery AM, Ross JA. Trends in childhood cancer incidence in the U.S. (1992-2004). Cancer 2008;112:416-32.
    Pubmed CrossRef
  2. Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 2014;64:83-103.
    Pubmed CrossRef
  3. National Cancer Institute. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Bethesda, MD: National Cancer Institute, 1999. (Accessed September 2, 2018, at
  4. Keegan TH, Ries LA, Barr RD, et al. Comparison of cancer survival trends in the United States of adolescents and young adults with those in children and older adults. Cancer 2016;122:1009-16.
    Pubmed CrossRef
  5. Pulte D, Gondos A, Brenner H. Trends in 5- and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990-2004. J Natl Cancer Inst 2008;100: 1301-9.
    Pubmed CrossRef
  6. Chessells JM; haemostasis and thrombosis task force, British committee for standards in haematology. Pitfalls in the diagnosis of childhood leukaemia. Br J Haematol 2001;114:506-11.
    Pubmed CrossRef
  7. Kratz A, Maloum K, O'Malley C, et al. Enumeration of nucleated red blood cells with the ADVIA 2120 Hematology System:an International Multicenter Clinical Trial. Lab Hematol 2006;12:63-70.
    Pubmed CrossRef
  8. Fang DZ, Sran G, Gessner D, et al. Cost and turn-around time display decreases inpatient ordering of reference laboratory tests: a time series. BMJ Qual Saf 2014;23:994-1000.
    Pubmed CrossRef
  9. Nahm CH, Choi JW, Lee J. Delta neutrophil index in automated immature granulocyte counts for assessing disease severity of patients with sepsis. Ann Clin Lab Sci 2008;38:241-6.
  10. Ahn C, Kim W, Lim TH, Cho Y, Choi KS, Jang BH. The delta neutrophil index (DNI) as a prognostic marker for mortality in adults with sepsis: a systematic review and meta-analysis. Sci Rep 2018;8:6621.
    Pubmed KoreaMed CrossRef
  11. Nam M, Son BH, Seo JE, Kim IR, Park CK, Kim HK. Improved diagnostic and prognostic power of combined delta neutrophil index and mean platelet volume in pediatric sepsis. Ann Clin Lab Sci 2018;48:223-30.
  12. Park JH, Byeon HJ, Lee KH, et al. Delta neutrophil index (DNI) as a novel diagnostic and prognostic marker of infection:a systematic review and meta-analysis. Inflamm Res 2017;66:863-70.
    Pubmed CrossRef
  13. Yoo J, Ahn SS, Jung SM, Song JJ, Park YB, Lee SW. Delta neutrophil index is associated with vasculitis activity and risk of relapse in ANCA-associated vasculitis. Yonsei Med J 2018;59:397-405.
    Pubmed KoreaMed CrossRef
  14. Ko DR, Jang JE, Chung SP, et al. Usefulness of the delta neutrophil index as an ancillary test in the emergency department for the early diagnosis of suspected acute promyelocytic leukemia. Leuk Lymphoma 2017;58:2387-94.
    Pubmed CrossRef
  15. Yoon SH, Kim SH, Lee MJ, Lee HJ, Lyu CJ, Kim MK. A 4-year-old girl presenting with facial palsy, found to have increased delta neutrophil index, and diagnosed with acute myeloid leukemia with extramedullary infiltration. Pediatr Emerg Med J 2017;4:25-8.
  16. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391-405.
    Pubmed CrossRef
  17. Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol 2005;77:598-625.
    Pubmed CrossRef
  18. Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase:an oxidative pathway for generating dysfunctional high-density lipoprotein. Chem Res Toxicol 2009;23:447-54.
    Pubmed KoreaMed CrossRef
  19. Hoy A, Leininger-Muller B, Kutter D, Siest G, Visvikis S. Growing significance of myeloperoxidase in non-infectious diseases. Clin Chem Lab Med 2002;40:2-8.
    Pubmed CrossRef
  20. Crisan D, David D, DiCarlo R. Use of myeloperoxidase mRNA as a marker for myeloid lineage in acute leukemias. Arch Pathol Lab Med 1996;120:828-34.
  21. Rytting ME, Kantarjian H, Albitar M. Acute lymphoblastic leukemia with Burkitt-like morphologic features and high myeloperoxidase activity. Am J Clin Pathol 2009;132:182-5.
    Pubmed CrossRef
  22. Zhou M, Findley HW, Zaki SR, Little F, Coffield LM, Ragab AH. Expression of myeloperoxidase mRNA by leukemic cells from childhood acute lymphoblastic leukemia. Leukemia 1993;7:1180-3.
  23. Oberley MJ, Li S, Orgel E, Phei Wee C, Hagiya A, O'Gorman MRG. Clinical significance of isolated myeloperoxidase expression in pediatric B-lymphoblastic leukemia. Am J Clin Pathol 2017;147:374-81.
    Pubmed CrossRef
  24. Jang MJ, Choi HW, Lee SY, et al. Application of bone marrow samples for discrimination of acute promyelocytic leukemia from other types of acute leukemia using the routine automated hematology analyzer. Int J Lab Hematol 2014;36:531-40.
    Pubmed CrossRef

October 2018, 25 (2)
Full Text PDF
Send to a friend

Cited By Articles
  • CrossRef (0)

Author ORCID Information
  • Moon Kyu Kim